Insight Molecular Diagnostics Inc.
NASDAQ: IMDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joshua Riggs
- Employees
- 46
- Headquarters
- Nashville, United States
- IPO year
- 2015
- Market cap
- $144.4M
- Website
- https://imdxinc.com
Loading IMDX…
Loading profile data…Frequently asked questions about IMDX
What does Insight Molecular Diagnostics Inc. (IMDX) do?
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnosti...
Where does IMDX trade?
Insight Molecular Diagnostics Inc. (IMDX) trades on the NASDAQ Capital Market.
What sector is IMDX in?
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Insight Molecular Diagnostics Inc.?
Joshua Riggs is the chief executive officer of Insight Molecular Diagnostics Inc. (IMDX).
Where is Insight Molecular Diagnostics Inc. headquartered?
Insight Molecular Diagnostics Inc. is headquartered in United States.
Does IMDX pay a dividend?
Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMDX go public?
Insight Molecular Diagnostics Inc. (IMDX) completed its initial public offering in 2015.